Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × Everolimus × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3 Gastrointestinal 2 Tumor-Agnostic 1 Thoracic 1 Breast 1

Conditions

Neoplasms 13 Neoplasm Metastasis 11 Neoplasms, Unknown Primary 1 Adenocarcinoma 1

Interventions

Oxaliplatin 12 Gemcitabine 12 Fluorouracil 9 Capecitabine 8 Leucovorin 7 Docetaxel 7 pembrolizumab 6 Irinotecan 5 zolbetuximab 4 regorafenib 4 Trastuzumab 4 Pemetrexed 4 Paclitaxel 4 S 1 (combination) 3 Radiotherapy 3 Nivolumab 3 Drug Therapy 3 Cisplatin 3 Bevacizumab 3 vandetanib 2 tislelizumab 2 sargramostim 2 lenvatinib 2 icotinib 2 camrelizumab 2 bemarituzumab 2 apatinib 2 Ramucirumab 2 Phlebotomy 2 Esophagectomy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00597506 2012-12-27

BEV/EV

Duke University

Phase 2 Completed

50 enrolled 7 charts

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡